Security record · archived quarter
CDTX
Cidara Therapeutics, Inc. · Healthcare · Biotechnology
6Tracked holders
+1Δ holders
579.82KShares held
$15.59MReported value
+1New positions
−0Exits
Momentum inputs (comparable managers):
holder breadth +20.0% ·
share flow +30.0% ·
net new positions +16.7%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
Ownership over time
Who holds it · Q4 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 369.95K | +765.3% | $9.94M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 95.62K | -2.2% | $2.57M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 53.07K | +0.3% | $1.43M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 35.96K | +158.3% | $966,605 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (passive) | 19.08K | n/a | $512,763 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 6.15K | New | $165,245 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $165,245 | 0.0% |
Exited
| No tracked exits this quarter. |
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q4 2024 ·
Methodology ·
Get this via the API